Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1018 RESPECT in elderly metastatic colorectal cancer
jRCTs031180145Phase 3Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab, oxaliplatin, fluorouracil, folinic acid and capecitabine in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival. Started Sep 2012; status: completed.
02
Drugs
bevacizumaboxaliplatinfluorouracilfolinic acidcapecitabine
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on jRCTs031180145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180145.